Verastem logo
Verastem
VSTM | NASDAQ
Chart Builder DCF Calculator
$7.70
-$0.48 (-5.87%)
At close: Nov 16, 2026, 4:00 PM ET
$7.78
+$0.08 (+1.04%)
After-hours: Nov 16, 2026, 7:30 PM ET

Verastem Company Profile

Company profile explained

Company Profile

Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-6766, a novel dual RAF/MEK inhibitor that operates by a "clamp" mechanism. This unique action effectively blocks the kinase activity of MEK and disrupts RAF's ability to phosphorylate MEK. The company is actively advancing several clinical trials. RAMP 201 is an adaptive, two-part, multicenter, randomized, open-label study designed to assess both the efficacy and safety of VS-6766, administered alone or in combination with defactinib. Defactinib is an oral small molecule inhibitor of focal adhesion kinase (FAK), and this trial targets patients with recurrent low-grade serous ovarian cancer. Simultaneously, Verastem is conducting RAMP 202, a Phase 2 trial focused on evaluating the safety profile of VS-6766 combined with defactinib. This particular study enrolls patients with non-small cell lung cancer (NSCLC) that harbors KRAS and BRAF mutations, specifically after they have undergone treatment with platinum-based regimens and immune checkpoint inhibitors. Verastem has also forged strategic partnerships to support its development efforts. It holds license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacturing rights of products incorporating VS-6766. Additionally, a similar agreement with Pfizer Inc. pertains to the research, development, production, and marketing of Pfizer's FAK inhibitors for various human applications, including therapeutic, diagnostic, and prophylactic uses. Further expanding its collaborations, Verastem has a clinical agreement with Amgen, Inc. to explore the synergistic potential of VS-6766 alongside Amgen's KRAS-G12C inhibitor, LUMAKRAS™, a combination being investigated in the Phase 1/2 RAMP 203 trial. Founded in 2010, Verastem, Inc. maintains its corporate headquarters in Needham, Massachusetts.

Key Executives

Name Position
Daniel W. Paterson President, Chief Executive Officer & Director
Daniel Calkins Chief Financial Officer
Cathy Carew Chief Organizational Effectiveness Officer
Jonathan Pachter Chief Scientific Officer
Julissa Viana Vice President of Corporate Communications & Investor Relations
Lori Horvat Executive Vice President of Portfolio Strategy & Operations
Mark J. Wanda Senior VP of Legal & Chief Compliance Officer
Michael Glen Kauffman President of Development & Director
Michelle Detwiler Co-Founder
Nathan Sanburn Chief Business Officer
Robert A. Weinberg Co-Founder & Chair of Scientific Advisory Board

Latest SEC Filings

Date Type Title
Oct 30, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 14, 2026 8-K Current Report
Oct 14, 2026 424B5 Filing
Oct 14, 2026 424B5 Filing
Oct 14, 2026 8-K Current Report
Oct 02, 2026 4 Filing
Oct 02, 2026 4 Filing
Sep 23, 2026 4 Filing
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 07, 2026 SC 13G Statement of acquisition of beneficial ownership b...
View All SEC Filings ➞
Verastem
Verastem logo
Country United States
IPO Date Jan 27, 2012
Industry Biotechnology
Sector Healthcare
Employees 102
CEO Daniel W. Paterson

Contact Details

117 Kendrick Street Needham, Massachusetts 02494 United States

Stock Details

Ticker Symbol VSTM
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001526119
CUSIP Number 92337C203
ISIN Number US92337C2035
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.